2013
DOI: 10.3390/ph6040469
|View full text |Cite
|
Sign up to set email alerts
|

Interactions of a Dopamine D1 Receptor Agonist with Glutamate NMDA Receptor Antagonists on the Volitional Consumption of Ethanol by the mHEP Rat

Abstract: Stimulation of the dopamine D1 receptor is reported to cause the phosphorylation of DARPP-32 at the thre34 position and activates the protein. If intracellular Ca2+ is increased, such as after activation of the glutamate NMDA receptor, calcineurin activity increases and the phosphates will be removed. This balance of phosphorylation control suggests that a D1 receptor agonist and a NMDA glutamate receptor antagonist should have additive or synergistic actions to increase activated DARPP-32 and consequent behav… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2016
2016
2016
2016

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 38 publications
0
1
0
Order By: Relevance
“…Previous studies utilizing dopamine agonists to enhance dopamine transmission provide support for this notion. Acute treatments of non‐selective dopamine receptor agonists, as well as selective D 1 and D 2 receptor agonists, decrease alcohol consumption in alcohol‐preferring rats (Weiss et al ; Dyr et al ; McMillen et al ). Further support comes from a recent study where the catechol‐o‐methyltransferase inhibitor, talcapone, reduced alcohol consumption in a cued‐access paradigm (McCane et al ).…”
Section: Discussionmentioning
confidence: 99%
“…Previous studies utilizing dopamine agonists to enhance dopamine transmission provide support for this notion. Acute treatments of non‐selective dopamine receptor agonists, as well as selective D 1 and D 2 receptor agonists, decrease alcohol consumption in alcohol‐preferring rats (Weiss et al ; Dyr et al ; McMillen et al ). Further support comes from a recent study where the catechol‐o‐methyltransferase inhibitor, talcapone, reduced alcohol consumption in a cued‐access paradigm (McCane et al ).…”
Section: Discussionmentioning
confidence: 99%